<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335301">
  <stage>Registered</stage>
  <submitdate>22/04/2010</submitdate>
  <approvaldate>25/05/2011</approvaldate>
  <actrnumber>ACTRN12611000540910</actrnumber>
  <trial_identification>
    <studytitle>Phase II study investigating the ability of Macrophage Inhibitory Cytokine-1 (MIC-1) and associated plasma markers to predict response to chemotherapy in men with metastatic castrate-resistant prostate cancer</studytitle>
    <scientifictitle>Phase II study investigating the ability of Macrophage Inhibitory Cytokine-1(MIC-1) and associated plasma markers to predict response to chemotherapy in men with metastatic castrate-resistant prostate cancer</scientifictitle>
    <utrn />
    <trialacronym>MIC-1 Study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic castrate-resistant prostate cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All patients will receive standard of care chemotherapy but will have sequential blood samples taken for analysis of plasma MIC-1 levels and the levels of associated biomarkers. Patients will be observed until death. The trial accrual will be 3 years but the overall duration of the study will be 5 years.</interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the ability of plasma MIC-1 and associated plasma biomarkers to predict the tumour response to chemotherapy compared to the conventional clinical endpoints of serum Prostate Specific Antigen (PSA), objective measurable response (as measured by CT scan and bone scan) and decrease in pain (as measured by 5-point pain scale).</outcome>
      <timepoint>6 months from baseline enrollment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the relationship between the plasma levels of MIC-1 and PSA response</outcome>
      <timepoint>Patients will be followed from enrollment until death which will generally be 12-24 months from baseline.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the ability of plasma MIC-1 and associated plasma biomarkers to predict overall survival.</outcome>
      <timepoint>Patients will be followed from enrollment until death which will generally be 12-24 months from baseline.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiological evidence of metastatic disease.
2.	Confirmed castrate-resistant prostate cancer (CRPC) with a minimum of 4 weeks having elapsed between the withdrawal of antiandrogens and enrolment.
3.	Patients must have a baseline serum PSA &gt; 10 ng/ml (referred to as PSA #1), and two consecutive rises in serum PSA (referred to as PSA #2 and PSA #3) greater than PSA #1 with each test performed at least one week apart. If PSA #3 is less than PSA #2, the patient remains eligible provided a fourth PSA (PSA #4) is greater than PSA #2.
4.	Age &gt; 18 years.
5.	Eastern Cooperative Oncology Group Performance status 0-3.
6.	A neutrophil count of at least 1500 per cubic millimetre and a platelet count of at least 100 000 per cubic millimetre.
7.	Normal bilirubin level and aspartate aminotransferase, alanine aminotransferase and serum creatinine no more than 1.5 times the upper limit of the normal range.
8.	Castrate testosterone levels due to either gonadotrophin-releasing hormone (GNRH) agonists or orchidectomy.
9.	Informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. No histological diagnosis of prostate cancer</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Cancer Australia</primarysponsorname>
    <primarysponsoraddress>PO Box 1201
Dickson ACT 2602</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Cancer Australia</fundingname>
      <fundingaddress>PO Box 1201
Dickson ACT 2602</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Garvan Institute for Medical Research</othercollaboratorname>
      <othercollaboratoraddress>384 Victoria Street
Darlinghurst
Sydney 2010 NSW</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Advanced prostate cancer is the second leading cause of cancer death in Australian men. Chemotherapy (Docetaxel) is effective in only 50% of patients with this disease. A molecule, MIC-1, is a potential predictive blood marker and mediator of Docetaxel resistance. This clinical trial will test whether the MIC-1 blood test is a predictor of Docetaxel resistance.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Missenden Rd
Camperdown
Sydney 2050 NSW</ethicaddress>
      <ethicapprovaldate>9/07/2010</ethicapprovaldate>
      <hrec>HREC/10/RPAH/289</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Ethics Committee</ethicname>
      <ethicaddress>Royal Prince Alfred Hospital 
Missenden Rd
CAMPERDOWN NSW 2050</ethicaddress>
      <ethicapprovaldate>9/07/2010</ethicapprovaldate>
      <hrec>HREC/10/RPAH/289</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A./Prof. Lisa Horvath</name>
      <address>Sydney Cancer Centre
Missenden Rd
Camperdown
NSW 2050</address>
      <phone>612 9515 5494</phone>
      <fax>612 9519 1546</fax>
      <email>lisa.horvath@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A./Prof. Lisa Horvath</name>
      <address>Sydney Cancer Centre
Missenden Rd
Camperdown
NSW 2050</address>
      <phone>612 9515 5494</phone>
      <fax>612 9519 1546</fax>
      <email>lisa.horvath@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mr Quoc Nguyen</name>
      <address>PRIMe
Cancer Program
Garvan Institute of Medical Science
384 Victoria St
DARLINGHURST NSW 2010</address>
      <phone>61 2 9295 8349</phone>
      <fax>61 2 9295 8422</fax>
      <email>q.nguyen@garvan.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>